Compare UEC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEC | GRFS |
|---|---|---|
| Founded | 2003 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.2B |
| IPO Year | N/A | 2006 |
| Metric | UEC | GRFS |
|---|---|---|
| Price | $17.14 | $9.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $15.80 | $10.15 |
| AVG Volume (30 Days) | ★ 10.6M | 435.4K |
| Earning Date | 12-10-2025 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | $49,750,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | N/A | $5.36 |
| Revenue Next Year | $153.62 | $5.15 |
| P/E Ratio | ★ N/A | $17.59 |
| Revenue Growth | ★ 189.19 | 7.31 |
| 52 Week Low | $3.85 | $6.19 |
| 52 Week High | $17.80 | $11.14 |
| Indicator | UEC | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 73.23 | 53.46 |
| Support Level | $11.65 | $8.79 |
| Resistance Level | $14.59 | $9.57 |
| Average True Range (ATR) | 0.92 | 0.23 |
| MACD | 0.43 | -0.02 |
| Stochastic Oscillator | 90.96 | 60.26 |
Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.